1
The Food and Drug Administration on Friday approved Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the US.
Zepbound, whose scientific name is tirzepatide, is now specifically approved for patients with both obesity and moderate to severe obstructive sleep apnea, or OSA, a condition characterized by interruptions in breathing during sleep.
This marks the first time Zepbound has been approved for an indication other than weight loss, which could give the company broader insurance coverage.
This article is exclusive to STAT+ subscribers
Unlock this article – plus daily news coverage and analysis from the biotech sector – by subscribing to STAT+.
Do you already have an account? Login
View all subscriptions
Subscribe to STAT+ to read the rest of this story.
Subscribe